Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver.
MacKinnon AC, Humphries DC, Herman K, Roper JA, Holyer I, Mabbitt J, Mills R, Nilsson UJ, Leffler H, Pedersen A, Schambye H, Zetterberg F, Slack RJ. MacKinnon AC, et al. Among authors: holyer i. Eur J Pharmacol. 2024 Dec 15;985:177077. doi: 10.1016/j.ejphar.2024.177077. Epub 2024 Nov 9. Eur J Pharmacol. 2024. PMID: 39528104
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, Phung D, Herman K, Holyer I, Poulsen KK, Dogterom P, Tantawi S, Zetterberg FR, Jacoby B, Schambye H, Lindmark B. Aslanis V, et al. Among authors: holyer i. Cancer Chemother Pharmacol. 2024 Nov;94(5):707-720. doi: 10.1007/s00280-024-04710-3. Epub 2024 Aug 21. Cancer Chemother Pharmacol. 2024. PMID: 39167148 Clinical Trial.
The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.
Comeglio P, Guarnieri G, Filippi S, Cellai I, Acciai G, Holyer I, Zetterberg F, Leffler H, Kahl-Knutson B, Sarchielli E, Morelli A, Maggi M, Slack RJ, Vignozzi L. Comeglio P, et al. Among authors: holyer i. Front Pharmacol. 2024 Jul 31;15:1430109. doi: 10.3389/fphar.2024.1430109. eCollection 2024. Front Pharmacol. 2024. PMID: 39144627 Free PMC article.
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
Hirst DJ, Bamborough P, Al-Mahdi N, Angell DC, Barnett HA, Baxter A, Bit RA, Brown JA, Chung CW, Craggs PD, Davis RP, Demont EH, Ferrie A, Gordon LJ, Harada I, Ho TCT, Holyer ID, Hooper-Greenhill E, Jones KL, Lindon MJ, Lovatt C, Lugo D, Maller C, McGonagle G, Messenger C, Mitchell DJ, Pascoe DD, Patel VK, Patten C, Poole DL, Shah RR, Rioja I, Stafford KAJ, Tape D, Taylor S, Theodoulou NH, Tomlinson L, Wall ID, Wellaway CR, White G, Prinjha RK, Humphreys PG. Hirst DJ, et al. Among authors: holyer id. J Med Chem. 2024 Jun 27;67(12):10464-10489. doi: 10.1021/acs.jmedchem.4c00959. Epub 2024 Jun 12. J Med Chem. 2024. PMID: 38866424
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer.
Zetterberg FR, Peterson K, Nilsson UJ, Andréasson Dahlgren K, Diehl C, Holyer I, Håkansson M, Khabut A, Kahl-Knutson B, Leffler H, MacKinnon AC, Roper JA, Slack RJ, Zarrizi R, Pedersen A. Zetterberg FR, et al. Among authors: holyer i. J Med Chem. 2024 Jun 13;67(11):9374-9388. doi: 10.1021/acs.jmedchem.4c00485. Epub 2024 May 28. J Med Chem. 2024. PMID: 38804039
12 results